The financing will support clinical trials, product development and team expansion as the business pursues international regulatory approvals.
"Our work in the US and the success of the trials we have run to date have demonstrated the potential of our technology and encouraged us to pursue other applications. With this financing and the backing of our investors we can accelerate our mission of delivering effective and non-invasive solutions for some of the most common and debilitating medical conditions."
Par Equity led the Series A round to support technology development and commercial expansion.
"We are delighted to continue working with Par Equity who have been very supportive of our company and our vision. This investment will enable us to continue to develop and commercialise our cutting-edge technology that addresses a major unmet need in the development of novel therapies that can significantly reduce costs of care and improve patient outcomes for millions of people worldwide."
The funding will support product development and international sales as the Belfast communications firm targets one million users.
"We are seeing organisations all over the world waking up to the strong business benefits of good employee comms. With the vast majority of people now carrying a smartphone, it makes an app the perfect way to connect with employees. We’ve designed the Thrive platform to be so easy to use that organisations can be up and running and improving the way they communicate and share information with employees in no time."
